Toshiba Global Commerce Solutions will showcase a broad range of retail technology solutions for retailers across all segments in booth #3623 at NRF 2026, including innovative AI-driven software, new ...
The global cell cryopreservation market size was valued at US$ 14.9 Bn in 2024 and is projected to reach US$ 104.8 Bn by 2035 ...
For any foreign (i.e. non-U.S.) companies out there that think you can blast American consumers with SMS messages or phone calls and escape liability, you better listen up. In King v. Bon Charge 2025 ...
For many years, the landscape of data center innovation has been dominated by solid-state electronics. The relentless pursuit of faster chips, denser racks and larger facilities has been the mantra ...
Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients with AML, ALL and MDS compared to a conventional allogeneic hematopoietic stem cell ...
Trial shows GRI-0621 improved lung function with signs of fibrosis resolution GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic ...
A Triple-Biotic Gut Health Formula Honored for Its Innovative Blend of Probiotics, Prebiotics, and Postbiotics Supporting Digestion, Energy, and Overall Wellness LOS ANGELES, Dec. 5, 2025 /PRNewswire/ ...
Financing led by DreamCIS will accelerate and expand development of the company's industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data ...
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Small Cap Annovis Bio Inc. (NYSE: ANVS) stock is trading higher on Monday, with a session volume of 12.29 million compared to the average volume of 615.12 thousand as per data from Benzinga Pro. A ...
Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from ...
Company preparing to initiate first-in-human Phase 1 study of CRMA-1001 in early 2026 nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results